Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
A Slc5a6-deficient mouse model reveals metabolically driven cardiomyopathy with therapeutic potential for vitamin-based intervention
Millie O. Fullerton, Lauren C. Phillips, Rachael E. Redgrave, Luke Spray, Vincent Haufroid, George Merces, Scott T. Kerridge, Gavin D. Richardson, Nathalie Mercier, Dominique Roland, Rebecca Crossley, Andrew D.H. Morgan, Joseph P. Dewulf, John Burn, Simon D. Bamforth, Helen M. Phillips
Millie O. Fullerton, Lauren C. Phillips, Rachael E. Redgrave, Luke Spray, Vincent Haufroid, George Merces, Scott T. Kerridge, Gavin D. Richardson, Nathalie Mercier, Dominique Roland, Rebecca Crossley, Andrew D.H. Morgan, Joseph P. Dewulf, John Burn, Simon D. Bamforth, Helen M. Phillips
View: Text | PDF
Research Article Cardiology Metabolism

A Slc5a6-deficient mouse model reveals metabolically driven cardiomyopathy with therapeutic potential for vitamin-based intervention

  • Text
  • PDF
Abstract

The sodium-dependent multivitamin transporter, encoded by SLC5A6, mediates cellular uptake of biotin and pantothenic acid, essential cofactors for energy metabolism. We identified 2 families with SLC5A6 mutations presenting with early-onset dilated cardiomyopathy (DCM). To investigate the link between vitamin deficiency and cardiomyopathy, we generated a cardiac-specific SLC5A6-knockout (Slc5a6cKO) mouse model and evaluated the impact of vitamin supplementation. Slc5a6cKO mice developed progressive cardiac dysfunction, culminating in cardiac pathology and premature death at 26 weeks; earlier stages exhibited cardiomyocyte hypertrophy, fibrosis, impaired coenzyme A synthesis, and metabolic imbalance, indicating progression toward cardiomyopathy. Cardiac magnetic resonance imaging and ECG confirmed progressive functional decline. Proteomic analysis revealed early mitochondrial metabolic disruption and extracellular matrix protein upregulation at 8 weeks, preceding overt cardiac dysfunction. Strikingly, vitamin supplementation from preconception onwards prevented the cardiac phenotype, preserving cardiac structure, function, morphology and survival. This paralleled the clinical outcome in one patient who received early vitamin treatment, compared with another who required a heart transplant without vitamin treatment. This study establishes a direct link between SLC5A6-mediated vitamin transport, mitochondrial function, and cardiac health. It highlights how vitamin deficiency contributes to cardiomyopathy pathogenesis and supports early vitamin supplementation as a potential therapeutic strategy for metabolic cardiomyopathies.

Authors

Millie O. Fullerton, Lauren C. Phillips, Rachael E. Redgrave, Luke Spray, Vincent Haufroid, George Merces, Scott T. Kerridge, Gavin D. Richardson, Nathalie Mercier, Dominique Roland, Rebecca Crossley, Andrew D.H. Morgan, Joseph P. Dewulf, John Burn, Simon D. Bamforth, Helen M. Phillips

×

Figure 7

Proteomic analysis revealed altered metabolism and increased fibrosis correlate with early indicators of cardiomyopathy in Slc5a6cKO mice.

Options: View larger image (or click on image) Download as PowerPoint
Proteomic analysis revealed altered metabolism and increased fibrosis co...
(A–E) Proteomic analysis at 8 weeks. PCA plot (A) and heatmap (B) illustrate that the proteome of the Slc5a6cKO mutants was distinct from the 3 other groups (control, vitamin-supplemented control, and vitamin-supplemented Slc5a6cKO hearts; n = 5 per group). (C and D) Volcano plots showing proteins with a significant (q < 0.05) fold change. (C) Under a normal diet, 1459 proteins with a fold change of ≤ –0.5 and ≥ 0.5 (red dots) and 478 proteins with a fold change of > –0.5 and < 0.5 (blue dots) were seen. (D) With vitamin supplementation, only 153 proteins with a fold change of ≤ –0.5 and ≥ 0.5 (orange dots) and 179 proteins with a fold change of > –0.5 and < 0.5 (green dots) were seen. (E) Venn diagram illustrating 124 of the proteins with a fold change of ≤ –0.5 and ≥ 0.5 remained significantly differentially expressed following vitamin supplementation. (F and G) IPA analysis of up- and downregulated proteins. For the mice on a normal diet, the majority of the enriched downregulated pathways in Slc5a6cKO mutant mice are linked to different components of the energy metabolism pathways in mitochondria (shown by asterisks in F) (F). In comparison, vitamin-supplemented Slc5a6cKO mutant mice only had downregulation of peroxisome-related pathways (G).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts